PMD81 Is there utility in clinical utility modeling for Diagnostic Technologies?  by Hertz, D. et al.
A52  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  
spending using Dartmouth Atlas of Health Care online data. Results: Among the 
155,841 patients, 5.9% had a depression diagnosis within 30 days after AMI admis-
sion. DACC-based ADRs captured considerable variation in depression diagnosis 
(IQR: 0.74 – 1.21) and relatively low and high zip code-level ADRs were dispersed 
across the United States. ADRs for depression diagnosis were statistically signifi-
cantly related to Medicare spending (Pearson correlation coefficient = 0.14, p < 0.01), 
but not local physician supply. ConClusions: Substantial geographic variation 
in depression diagnosis exists across the United States. Areas with higher general 
healthcare spending were more likely to have higher depression diagnosis rates. 
Further research is needed to explore if geographic variation in diagnosis affect 
health and economic outcomes to address whether depression was correctly, over- 
or under-diagnosed.
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urinary tract infection among the sglt 2 inhibitors:  
a meta-analysis of 19 ranDomizeD controlleD trials
Gangal N.S., Kelton C., Heaton P.C.
University of Cincinnati, Cincinnati, OH, USA
oBJeCtiVes: The goal of this meta-analysis was to determine if within the 
sodium- glucose cotransporter 2 (SGLT 2) inhibitors class, any individual drug 
increases the risk of urinary tract infection (UTI). MetHoDs: Data base search 
was conducted using Medline, PubMed, and Google Scholar. Study included trials 
of FDA approved SGLT 2 inhibitors canagliflozin, dapagliflozin and empagliflozin. 
To ensure internal validity of the selected studies, only randomized controlled 
trials which included patients with diabetes were included. Any trials with any 
special groups of patients, for example, patients with cardiovascular disease were 
excluded. Non-randomized trials, case reports, editorials, letters to the editors, 
and studies with no comparison group were excluded. Trials which did not report 
UTI as a side effect were excluded. A meta-analysis was conducted and data was 
pooled using odds ratio and 95% confidence intervals. All analysis was performed 
using SAS version 9.4. Results: When the three drugs were compared, there 
was no significant difference in odds of developing a UTI. Sensitivity analyses 
were performed by excluding, in turn, the contribution of each study to the meta-
analysis data. There was no significant difference in the results. ConClusions: 
Although the study reinforced the finding that urinary tract infection is one of the 
major adverse events caused by this class of antidiabetic drugs, this meta-analysis 
suggested that there was no significant difference in risk of UTIs among the three 
SGLT 2 inhibitors on the market.
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stuDy of patient relateD outcomes of type 2 Diabetes anD 
comparative analysis of pioglitazone sales pre anD post ban in 
mumbai,inDia
Yande S., Hegde P., Velankar K., Dhumal T., Majumdar A.
Bombay College Of Pharmacy, Mumbai, India
intRoDuCtion: Diabetes mellitus is the leading disorder in India. 
Thiazolidinediones have been marketed since 1997 and are effective glucose low-
ering drugs, but individual drugs of this category like Pioglitazone have been linked 
to serious side effects like bladder cancer and hence banned in India. oBJeCtiVes: 
A survey was conducted to evaluate the prescription trends of type II diabetes 
in Mumbai, India and the adverse drug reactions associated with it. To evaluate 
the effect of sales of pioglitazone after its ban was removed. To observe the vari-
ation in prescription trends as compared to normal trends in case of drug resist-
ance. MetHoDs: Two sets of questionnaires were prepared which captured patient 
demographics, prescription trends and adverse drug reactions of type II diabetes 
patients in Mumbai, India.The questionnaires targeted 75 drug stores, 40 General 
Practitioners and 3 government hospitals. Results: Average number of prescrip-
tions received by the pharmacist under the survey were 30-40 per week. Males are 
more affected than females. The trend of prescriptions prescribed by the general 
practitioners is similar to that of prescriptions received by the drug stores. Metformin 
is majorly prescribed followed by Glimepiride, Voglibose, Pioglitazone. Contrasting 
results were obtained with respect to Pioglitazone on comparing the prescription 
trends of doctors to the pharmacists as it was often prescribed by doctors after its 
ban was removed but its sales had not increased. The most number of adverse reac-
tions were shown by Metformin and Glimepiride followed by Pioglitazone,Gliptins 
and Incretin Mimetics showed minimum side effects. ConClusions: From our 
results it was observed that there was no increase in the sales of Pioglitazone. 
Patients were treated with Metformin and Metformin-Glimepiride combination as 
first line treatment. Pioglitazone and insulin are most commonly prescribed in 
case of a drug resistance. Dose variations were suggested by general practitioners 
in case of a drug resistance.
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comparative outcomes of testosterone therapy versus no 
treatment in hypogonaDic men
Noone J., Blanchette C.M., Van Doren B.A., Zacherle E.
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oBJeCtiVes: Testosterone therapy for the treatment of hypogonadism in older 
men is controversial. Previous studies on benefits have been inconclusive and 
there is the belief that the known potential for negative cardiac outcomes out-
weighs any benefit. We used a sample of Medicare patients to test the time from 
diagnosis of hypogonadism to positive and negative events related to treating 
hypogonadism MetHoDs: Using a 5% random sample of Medicare LDS claims 
larly in liver surgical bleeding. Caution must be taken in interpreting results given 
some patient differences. A head-to-head trial comparison may be necessary to 
confirm differences between products.
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effect of hyDrophilic coating isotonic to urine on infections anD 
complications among users of intermittent urinary catheters
Neovius K.1, Svensson J.1, Åberg-Håkansson M.2, Lundqvist T.2
1Aux Analysis, Stockholm, Sweden, 2Wellspect HealthCare, Mölndal, Sweden
oBJeCtiVes: Infections and urethral trauma are common complications among 
patients using intermittent urinary catheters. The objective of this study was to 
investigate the effect on complications of switching to a catheter with hydrophilic 
coating isotonic to urine. MetHoDs: A questionnaire was sent to 694 individuals 
performing daily intermittent urinary catheterization in Europe and the USA. The 
participants were asked to report infections and complications, as well as cur-
rent and previous catheter type if applicable. Only patients reporting to currently 
be using a catheter type with hydrophilic coating isotonic to urine were included 
in the study. The patients who had previously switched catheters were asked to 
estimate their current infections, complications and problems as much less, less, 
same, more or much more compared to before the switch. Wilcoxon signed rank 
tests were carried out to detect changes in level of consequences after switching. 
Analyses were performed separately for patients who switched but stayed on cath-
eters with hydrophilic coating isotonic to urine and patients who switched from 
another catheter type. Results: The initial response rate was 57% (n= 391) of which 
74% (n= 288) were using catheters with hydrophilic coating isotonic to urine. 129 
patients reported to have switched catheters, 41 (32%) stayed on the same catheter 
type, i.e. hydrophilic coating isotonic to urine, and 88 (68%) switched from another 
catheter type. Among those patients who switched from another catheter type to a 
catheter with hydrophilic coating isotonic to urine, an average of 15% reported more 
and 32% reported less infections (p= 0.042), UTIs (p= 0.041), complications (p= 0.062) 
and general problems (p= 0.001). The corresponding numbers for the patients who 
stayed on catheters with hydrophilic coating isotonic to urine were not statisti-
cally significant. ConClusions: This study indicates that patients performing 
daily intermittent catheterization can benefit from switching to a catheter with 
hydrophilic coating isotonic to urine.
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is there utility in clinical utility moDeling for Diagnostic 
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Hertz D., Taggart C., Waterman J., Armstrong S.
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oBJeCtiVes: Demonstrating clinical utility is a challenge for diagnostic companies; 
MolDx denied 40% of CMS applications due to insufficient clinical utility data. Trials 
to prove clinical utility can be expensive and lengthy. Modeling can be a relatively 
inexpensive method in establishing clinical utility for a novel diagnostic. The objec-
tive of this study was to determine the utility of and identify requirements and hur-
dles for developing clinical utility models. MetHoDs: We conducted a qualitative 
review of 15 clinical utility models for novel diagnostics across diverse therapeutic 
areas and encompassing screening, diagnostic and monitoring tests. Models were 
assessed based on data requirements, validity of outcomes, and ability to secure 
reimbursement. Results: Clinical utility depends on: (1) test performance (rela-
tive to standard of care), (2) physician practice change (confidence in test results), 
(3) patient compliance/behavioral change, (4) availability and proven benefits of 
alternative treatment course, (5) and/or reductions in adverse events. Modeling for 
clinical utility is most effective in areas where clear treatment protocols exist and 
evidence supporting the efficacy of an alternative treatment is robust. Evidence sup-
porting practice change and patient compliance are frequently unknown, but may 
be informed by literature, claims analysis and/or EMR data. Modeling clinical utility 
is most challenging when treatment guidelines are broad and outcomes evidence is 
not well differentiated. ConClusions: Modeling is a logical first step in assessing 
clinical utility. It’s a cost-effective way of identifying a target population and best 
test placement in the continuum of care through comparison of alternative strate-
gies. Additionally, it can be useful in identifying evidence gaps and prioritizing data 
collection. However unless the data supporting the model is strong, it is insufficient 
on its own to secure reimbursement. Analysis of claims and EMR data can be an 
excellent data source for supporting diagnostic utility modeling.
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oBJeCtiVes: Depression treatment after acute myocardial infarction (AMI) is impor-
tant to improve outcomes. Identification of geographic variation in depression 
diagnosis is a needed first step to understand practice variation and its outcome 
implications. The objective of this study was to assess the extent of geographic 
variation in depression diagnosis of Medicare patients after AMI. MetHoDs: A ret-
rospective cohort of Medicare beneficiaries hospitalized with AMI during 2007-2008 
(no AMI and depression diagnosis in the previous year) was included. Depression 
diagnosis was identified if a patient had a depression diagnosis within 30 days 
after AMI admission. Using driving-area-for-clinical-care (DACC) method, zip code-
specific area diagnosis ratios (ADRs) were estimated as number of patients receiving 
a depression diagnosis divided by the sum of predicted probabilities of receiving 
a depression diagnosis across patients in a driving-time zip code. Linear regres-
sion yielded predicted probability estimates of each patient receiving a diagnosis 
based on demographics, prior comorbidities/treatments, climate, and neighborhood 
characteristics. Maps were created to contrast geographic variation in depression 
diagnosis based on ADRs. Overall healthcare utilization was measured by Medicare 
